3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
15
Esophageal Neoplasms
12
Colorectal Neoplasms
9
Stomach Neoplasms
6
Rectal Neoplasms
6
Esophageal Squamous Cell Carcinoma
6
Pancreatic Neoplasms
5
Neoplasms
4
Liver Neoplasms
4
Cholangiocarcinoma
4
Neoplasm Metastasis
3
Melanoma
3
Carcinoma, Renal Cell
3
Liver Diseases
2
Gastrointestinal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Adenocarcinoma
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Unresectable Hepatocellular Carcinoma
1
Unresectable Biliary Tract Cancer
1
Triple Negative Breast Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Interventions
Gemcitabine
61
Cisplatin
39
Oxaliplatin
31
Capecitabine
29
Fluorouracil
22
Leucovorin
20
Irinotecan
12
pembrolizumab
11
130-nm albumin-bound paclitaxel
10
durvalumab
9
Erlotinib Hydrochloride
8
Trastuzumab
7
Bevacizumab
7
Taxes
6
Platinum
6
Magnetic Resonance Spectroscopy
6
Biopsy
6
Albumin-Bound Paclitaxel
6
1,2-diaminocyclohexaneplatinum II citrate
6
Specimen Handling
5
Sorafenib
5
Radiotherapy
5
Docetaxel
5
Carboplatin
5
Immunohistochemistry
4
trifluridine tipiracil drug combination
3
dehydroftorafur
3
atezolizumab
3
Watchful Waiting
3
Tegafur
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gallbladder Neoplasms
×
Immunotherapy
×
Gastrointestinal
×
Clear all
NCT04333927
2020-06-23
ACCORD
Sun Yat-sen University
Phase 2
Unknown
92 enrolled